Cellectar Biosciences Faces Nasdaq Compliance Issue

Cellectar Biosciences (CLRB) has provided an announcement.

The Company has been notified by Nasdaq that it’s out of compliance due to a delay in filing its quarterly financial report. This is because the Company is reassessing its accounting for warrants issued in a previous financing and needs to restate financial statements for several past periods. They anticipate this restatement process will take around six weeks, after which they’ll file the overdue quarterly report. Despite this, the Company’s stock continues to be listed on the Nasdaq Capital Market.

Find detailed analytics on CLRB stock on TipRanks’ Stock Analysis page.